| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;40:23.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Cardiac and Thoracic Department, University of Pisa (V.D.B., A.B., D.G., M.M.); and the Department of Clinical and Experimental Medicine, University of Padua Medical School (G.P.R., C.G., A.S., M.C., R.S., A.C.P.), Italy.
Correspondence to Prof Gian Paolo Rossi, MD., F.A.C.C, F.A.H.A., Department of Clinical and Experimental Medicine, Clinica Medica 4, Policlinico Universitario, via Giustiniani, 2, 35126 Padova, Italy. E-mail gianpaolo.rossi{at}unipd.it
| Abstract |
|---|
|
|
|---|
0.002) but not for casual blood pressure values, demographics, and duration of hypertension. Compared with hypertensive patients, PA patients showed a higher LV mass index (53.7±1.8 versus 45.5±2.0 g/m2.7; P=0.008) and lower values of the cyclic variation index of the myocardial mean gray level of septum (CVIs; -12.02±5.84% versus 6.06±3.08%; P=0.012) and posterior wall (-11.13±6.42% versus 8.63±9.62%; P=0.012). A regression analysis showed that CVIs was predicted by the PQ duration, supine plasma renin activity, plasma aldosterone, and age, which collectively accounted for
36% of CVIs variance. PA is associated with alterations of myocardial textures that suggest increased collagen deposition and that can explain both the dependence of LV diastolic filling from presystole and the prolongation of the PQ interval.
Key Words: hypertension, endocrine aldosterone myocardial hypertrophy fibrosis echocardiography
| Introduction |
|---|
|
|
|---|
Fibroblasts constitute the vast majority (>90%) of nonmyocyte cells in the heart; they can increase the production of extracellular matrix on exposure to a variety of injuries, including pressure overload. The latter seems to be only one of the determinants of CF, because it was experimentally shown, both in vitro and in vivo, that CF in both ventricles was linked to activation of the renin-angiotensin-aldosterone system6 and that it could be prevented by non-antihypertensive dosages of spironolactone.7
Thus, angiotensin II and aldosterone play important roles in the heart (for review, see Swynghedauw8). Angiotensin II induces cardiomyocyte hypertrophy in both ventricles,9 stimulates collagen synthesis by fibroblasts, and regulates collagen degradation by blunting the activity of matrix metalloproteinase-1, the key enzyme of collagen degradation.8 Aldosterone is extracted through the human heart through a spironolactone-sensitive pathway10 and promotes CF by acting through different pathogenic mechanisms.8,11 It increases types I and III procollagen mRNA in both ventricles, although it does not seem to influence matrix metalloproteinase-1 activity in cultured cardiac fibroblast preparations.12 Aldosterone may also act on the cardiac angiotensin II receptor, because its administration, along with a high-salt diet, increased angiotensin II type 1 (AT-1) receptor density in the left ventricle of rats; this increase was prevented by both spironolactone and losartan.13 Thus, aldosterone might cause extracellular matrix deposition by enhancing the transcription of collagen type I and III genes and by augmenting the effects of angiotensin II on AT-1 receptors.14
Primary aldosteronism (PA) offers a unique opportunity for investigating the role of excess aldosterone in humans, independent of that of angiotensin II, which is suppressed. We previously reported that in white PA patients there is an excess of LVH15; this finding was thereafter confirmed in Japanese PA patients.16 Doppler flow velocity indexes of early diastole transmitral flow are decreased compared with those from patients with primary (essential) hypertension (EH). These alterations were more marked in patients with a Conns adenoma, in whom aldosterone excess and renin suppression were also more prominent, and were corrected by adrenalectomy, 17 thus indicating a causative role of excess aldosterone in CF. To prove this link conclusively, histological analysis of myocardial biopsies would be necessary, but this is unfeasible for ethical reasons. However, newer noninvasive technologies, such as the videodensitometric analysis of myocardial texture that have proven to be accurate for assessing CF,18,19 provide a tool to reexamine this question. Therefore, we sought to compare myocardial texture indexes between consecutive PA and EH patients.
| Methods |
|---|
|
|
|---|
Echocardiography
All patients were in sinus rhythm, and none had any valvular or ischemic heart disease. Conns adenoma patients were studied before adrenalectomy. M-mode and 2D echocardiograms and Doppler analysis were performed with a commercially available apparatus (Hewlett-Packard Sonos 2500). The measurement of left ventricular (LV) diameters and posterior wall and septum thickness and the calculation of LV mass and relative wall thickness were performed as described previously.17 LV mass was normalized for height2.7 to obtain the LV mass index (LVMI). Criteria for concentric and eccentric LVH and LV remodeling have been described previously.17
A single reader (A.S.) blindly performed the following measurements on a pulsed Doppler transmitral flow velocity profile: early diastolic (E wave) peak flow velocity (PFVE), diastolic peak flow velocity at atrial contraction (A wave, PFVA), their ratio (PFVE/PFVA), E wave integral (Ei), A wave integral (Ai), their ratio (Ei/Ai), and the atrial contribution to LV filling (ACLVF), as reported previously.17
Blood pressure was measured while the patients were off medications using a mercury sphygmomanometer with phase V of Korotkoff for diastolic pressure, before and after echocardiography.
Videodensitometry
To achieve a precise and reproducible sampling of textural parameters, the gain settings and compensation profiles were adjusted for all subjects to obtain uniform myocardial brightness throughout the echocardiogram. The gray scale transfer function was adjusted to be linear for the entire video signal range; no reject, enhancement, or dynamic ranges were used; and a 25 to 30 dB amplification at a depth of 18 cm was set. The optimal echocardiographic images were transferred to a calibrated video digitization system and converted into 256x256 pixels of 256 gray levels, each with a real-time videodigitizer (Tomtec Imaging Systems).19,22 Each cardiac cycle was automatically divided into 12 frames independently of heart rate. The images corresponding to the end-diastolic and end-systolic phases, all in long-axis projection, were selected with an optimal visualization of both the interventricular septum and the LV posterior wall.
The regions of interest for texture analysis were chosen by consensus of 2 observers who were blinded to the diagnosis group, as described previously.22 The regions of interest, which were always the same size (32x42 pixels), were placed in the same location in the septum (midseptum) and in the posterior wall (midposterior) in both end-systolic and end-diastolic frames. We also considered the delay or phase-shift of the cyclic variation in all septum and posterior wall samplings; a time delay of 1.0 corresponded to a peak near end-diastole, and a nadir near end-systole was found in mean gray level cyclic variation.19,22 A histogram of the gray level distribution was generated for each region of interest.
The mean gray level of each cavity region (background signal) was subtracted from the absolute mean gray level obtained for each regions of interest. A quantitative analysis of the shape of each distribution was also performed using skewness and kurtosis. The cyclic variation index (CVI) of the myocardial gray level amplitude was calculated as described previously.22 Measurements were averages of at least 5 consecutive cardiac cycles. Reproducibility was estimated by analyzing, in a blinded fashion, all recordings on 2 separate occasions by the same (intraobserver variability) or different (interobserver variability) investigators. Intraobserver and interobserver coefficients of variation averaged 7.5% and 10.2%, respectively. The intraclass correlation coefficient for septum mean gray level was 0.92 for diastolic and 0.90 for systolic samples; for posterior wall mean gray level, it was 0.89 for diastolic and 0.91 for systolic samples.
Statistical Analysis
Results are presented as mean±SD (or SEM or range); comparison between groups was performed with Students t test for unpaired data or the Mann-Whitney test. The relationship between individual variables was examined by scatter plot analysis and correlation matrix followed by a stepwise linear regression analysis on the CVI of the septum (CVIs) of the variables that were of interest in the scatter plot analysis.
An expanded Methods section can be found in an online data supplement available at http://www.hypertensionaha.org.
| Results |
|---|
|
|
|---|
|
|
Videodensitometric Analysis of the Left Ventricle Myocardial Texture
The Figure shows the results of the videodensitometric measurements of the interventricular septum (CVIs), LV posterior wall (CVIpw), and the mean of the 2 indexes (CVIm). Compared with EH patients, PA patients had lower values of both CVIs and CVIm, whereas the difference of CVIpw was of borderline statistical significance, mainly because of an inferior reproducibility of this measurement compared with that of measurements of the septum. CVIs correlated with CVIpw (r=0.528, P=0.02), PQ duration (r=-0.0451, P=0.009), baseline supine PRA (r=0.435, P=0.013), LVMI, and the Doppler-derived index of LV filling PFVA (r=-0.340, P=0.041), whereas no significant correlation with plasma aldosterone levels was detected. However, aldosterone entered in the regression analysis on CVIs (ß=0.464, P=0.042), as did PQ duration (ß=0.563, P=0.022), baseline supine PRA (ß=0.503, P=0.033), and age (ß=0.338, P=0.135). This model significantly (P=0.026) predicted CVIs and accounted for
36% (adjusted R2=0.357) of its variance.
|
| Discussion |
|---|
|
|
|---|
The present results provide an important novel piece of information, which is relevant for the understanding of all the aforementioned changes in LV mass and filling. Despite the modest increase of LV mass and the lack of overt clinical signs of diastolic dysfunction, the PA patients exhibited greater alterations of videodensitometric indexes of LV myocardial texture, compared with demographically and hemodynamically similar EH patients. The changes of myocardial texture involved the interventricular septum and the LV posterior wall and were evident in PA patients with quite small Conns adenoma, suggesting that these changes occur early in the course of the disease.
We could identify only a small series of suitable EH patients to match our PA patients within the time span of this study. However, these EH patients showed values of CVIs and CVIpw that were almost identical to those found in a larger series of EH patients with normal LV mass and concentric remodeling, 24 thus making a selection bias unlikely. Furthermore, in another series of EH patients who had a marked concentric LVH, CVIs values were quite similar to those seen in the PA patients, who had a much lower LV mass index.24 Thus, excess aldosterone can act synergistically with the pressure overload in altering myocardial texture.
The alterations in the acoustic properties of myocardium might be explained on several grounds. It is possible that an increased deposition of extracellular matrix and collagen, occurring as a result of the excess aldosterone in PA, could create increased scattering in systole. One of the mechanisms that explains the loss of acoustic myocardial reflectivity seen in normal subjects in systole is the shortening of myocardial fibers during contraction. Therefore, an augmented collagen content, which was found in postmortem specimens of hearts from a few patients with autopsy-proven adrenal adenoma,25 could decrease the normal cyclic variation of scattering by impairing the intrinsic contractile properties of the heart. Another mechanism relates to the pressure-volume overload which, by stretching the myocardium, could change the orientation, structure, or geometry of both the muscle fibers and the collagen network, thereby influencing the acoustic properties of the myocardium. Whatever the mechanisms, our results indicate that videodensitometric analysis of myocardial texture could be a sensitive test, along with indexes of LV mass and LV filling changes, for the early identification of cardiac involvement in patients with PA.
To gain further mechanistic insight, we examined the relationships between individual variables and videodensitometric indexes of CF. We found a direct relationship of CVIs with PRA, indicating that lower PRA values are associated with higher collagen deposition in the heart. A significant inverse relationship with duration of PQ interval, LVMI, and PFVA was also found, thus showing that increased collagen deposition is associated with prolongation of the PQ interval, which accords well with previous findings,17 and with increasing LV mass and peak flow velocity rate during presystole. A regression analysis also identified PQ duration, baseline supine PRA, plasma aldosterone, and age as predictors of CVIs. Because the ECG PQ interval reflects conduction time from the sinoatrial node through the atria, the atrioventricular node, and the Purkinje fibers to the left ventricle, the highly significant (P=0.009) correlation of CVIs with PQ duration suggests that CF can also be an important determinant of the latter.
| Conclusions |
|---|
|
|
|---|
Perspectives
The present results might be relevant for understanding the LV changes of patients with secondary aldosteronism, such as those with congestive heart failure in whom blockade of the mineralocorticoid receptor with spironolactone strikingly improved outcome,26 decreased LV mass index and LV end- diastolic diameter and volume, and lowered biochemical markers of myocardial fibrosis and hypertrophy.27 The newer technologies, such as backscatter analysis and MRI, that are being developed to assess myocardial texture and extracellular matrix might eventually be useful to confirm the detrimental role of excess aldosterone on the heart found in this study in congestive heart failure patients with hyperaldosteronism.
| Acknowledgments |
|---|
Received March 29, 2002; accepted May 3, 2002.
| References |
|---|
|
|
|---|
2. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998; 16: 10311041.[CrossRef][Medline] [Order article via Infotrieve]
3. Agabiti-Rosei E, Muiesan ML. Left ventricular diastolic function in essential hypertension. Contrib Nephrol. 1994; 106: 174178.[Medline] [Order article via Infotrieve]
4. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res. 1991; 69: 107115.
5. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991; 83: 17711779.
6. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990; 67: 13551364.
7. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993; 71: 12A16A.[CrossRef][Medline] [Order article via Infotrieve]
8. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999; 79: 215262.
9. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension. 2000; 35: 985991.
10. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Horie H, Sugimoto Y, Kinoshita M. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36: 838844.
11. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension. 2001; 38: 12271232.
12. Brilla CG, Maisch B, Weber KT. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Invest. 1993; 71: S35S41.[Medline] [Order article via Infotrieve]
13. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension. 1994; 24: 3036.
14. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995; 269: E657E662.[Medline] [Order article via Infotrieve]
15. Rossi GP, Sacchetto A, Visentin PA, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996; 27: 10391045.
16. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension. 1997; 29: 723727.
17. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conns adenoma. Circulation. 1997; 95: 14711478.
18. Lucarini AR, Gigli G, Lattanzi F, Picano E, Mazzarisi A, Iannetti M, Landini L. Regression of hypertensive myocardial hypertrophy does not affect ultrasonic myocardial reflectivity: a tissue characterization study. J Hypertens. 1994; 12: 7379.[Medline] [Order article via Infotrieve]
19. Di Bello V, Talarico L, Picano E, Giorgi D, Bertini A, Paterni M, Giusti C. Increased myocardial echo density in left ventricular pressure and volume overload in human aortic valvular disease: an ultrasonic tissue characterization study. J Am Soc Echocardiogr. 1997; 10: 320329.[Medline] [Order article via Infotrieve]
20. Rossi GP, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, Perazzoli F, Pessina AC. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf). 1998; 49: 713723.[CrossRef][Medline] [Order article via Infotrieve]
21. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab. 2001; 86: 10831090.
22. Di Bello V, Pedrinelli R, Giorgi D, Bertini A, Talarico L, Caputo MT, Massimiliano B, DellOmo G, Paterni M, Giusti C. Ultrasonic videodensitometric analysis of two different models of left ventricular hypertrophy. Athletes heart and hypertension. Hypertension. 1997; 29: 937944.
23. Pai RG, Shah PM. Echo-Doppler evaluation of left ventricular diastolic function. ACC Curr J Rev. 1994; 3: 3033.
24. Di Bello V, Pedrinelli R, Giorgi D, Bertini A, Bianchi M, Paterni M, Romano MF, DellOmo G, Giusti C. Ultrasonic myocardial texture versus doppler analysis in hypertensive heart: a preliminary study. Hypertension. 1999; 33: 6673.
25. Campbell SE, Diaz-Arias AA, Weber KT. Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press. 1992; 1: 149156.[Medline] [Order article via Infotrieve]
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709717.
27. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001; 37: 12281233.
This article has been cited by other articles:
![]() |
J. Peters, T. Schluter, T. Riegel, B. S. Peters, A. Beineke, U. Maschke, N. Hosten, J. J. Mullins, and R. Rettig Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1845 - H1852. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Martin-Fernandez, M.ķa Miana, N. De las Heras, G. Ruiz-Hurtado, M.ķa Fernandez-Velasco, M. Bas, S. Ballesteros, V. Lahera, V. Cachofeiro, and C. Delgado Cardiac L-type calcium current is increased in a model of hyperaldosteronism in the rat Exp Physiol, June 1, 2009; 94(6): 675 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Giacchetti, V. Ronconi, S. Rilli, M. Guerrieri, F. Turchi, and M. Boscaro Small tumor size as favorable prognostic factor after adrenalectomy in Conn's adenoma Eur. J. Endocrinol., April 1, 2009; 160(4): 639 - 646. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lopez-Andres, C. Inigo, I. Gallego, J. Diez, and M. A. Fortuno Aldosterone Induces Cardiotrophin-1 Expression in HL-1 Adult Cardiomyocytes Endocrinology, October 1, 2008; 149(10): 4970 - 4978. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Muiesan, M. Salvetti, A. Paini, C. Agabiti-Rosei, C. Monteduro, G. Galbassini, E. Belotti, C. Aggiusti, D. Rizzoni, M. Castellano, et al. Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism Hypertension, September 1, 2008; 52(3): 529 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Gomez-Sanchez, D. G. Romero, A. F. de Rodriguez, M. P. Warden, Z. Krozowski, and C. E. Gomez-Sanchez Hexose-6-Phosphate Dehydrogenase and 11{beta}-Hydroxysteroid Dehydrogenase-1 Tissue Distribution in the Rat Endocrinology, February 1, 2008; 149(2): 525 - 533. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Brown Aldosterone and Vascular Inflammation Hypertension, February 1, 2008; 51(2): 161 - 167. [Full Text] [PDF] |
||||
![]() |
C. Catena, G. Colussi, E. Nadalini, A. Chiuch, S. Baroselli, R. Lapenna, and L. A. Sechi Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment Arch Intern Med, January 14, 2008; 168(1): 80 - 85. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Agabiti-Rosei, M. L. Muiesan, and M. Salvetti Review: New approaches to the assessment of left ventricular hypertrophy Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 119 - 128. [Abstract] [PDF] |
||||
![]() |
C. Catena, G. Colussi, R. Lapenna, E. Nadalini, A. Chiuch, P. Gianfagna, and L. A. Sechi Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism Hypertension, November 1, 2007; 50(5): 911 - 918. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Stas, A. Whaley-Connell, J. Habibi, L. Appesh, M. R. Hayden, P. R. Karuparthi, M. Qazi, E. M. Morris, S. A. Cooper, C. D. Link, et al. Mineralocorticoid Receptor Blockade Attenuates Chronic Overexpression of the Renin-Angiotensin-Aldosterone System Stimulation of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Cardiac Remodeling Endocrinology, August 1, 2007; 148(8): 3773 - 3780. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Auchus, D. W. Chandler, S. Singeetham, N. Chokshi, F. E. Nwariaku, B. L. Dolmatch, S. A. Holt, F. H. Wians Jr., S. C. Josephs, C. K. Trimmer, et al. Measurement of 18-Hydroxycorticosterone during Adrenal Vein Sampling for Primary Aldosteronism J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2648 - 2651. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rahman, A. Nishiyama, P. Guo, Y. Nagai, G.-X. Zhang, Y. Fujisawa, Y.-Y. Fan, S. Kimura, N. Hosomi, K. Omori, et al. Effects of Adrenomedullin on Cardiac Oxidative Stress and Collagen Accumulation in Aldosterone-Dependent Malignant Hypertensive Rats J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1323 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Turchin, C. Z. Guo, G. K. Adler, V. Ricchiuti, I. S. Kohane, and G. H. Williams Effect of Acute Aldosterone Administration on Gene Expression Profile in the Heart Endocrinology, July 1, 2006; 147(7): 3183 - 3189. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M. E. Safar, and J.-J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1243 - 1248. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Glorioso, F. Filigheddu, P. P. Parpaglia, A. Soro, C. Troffa, G. Argiolas, and P. Mulatero 11{beta}-Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension Eur. Heart J., March 1, 2005; 26(5): 498 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Struthers The clinical implications of aldosterone escape in congestive heart failure Eur J Heart Fail, August 1, 2004; 6(5): 539 - 545. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Vasan, J. C. Evans, E. J. Benjamin, D. Levy, M. G. Larson, J. Sundstrom, J. M. Murabito, F. Sam, W. S. Colucci, and P. W. F. Wilson Relations of Serum Aldosterone to Cardiac Structure: Gender-Related Differences in the Framingham Heart Study Hypertension, May 1, 2004; 43(5): 957 - 962. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Pu, M. F. Neves, A. Virdis, R. M. Touyz, and E. L. Schiffrin Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling Hypertension, July 1, 2003; 42(1): 49 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kozakova, S. Buralli, C. Palombo, G. Bernini, A. Moretti, S. Favilla, S. Taddei, and A. Salvetti Myocardial Ultrasonic Backscatter in Hypertension: Relation to Aldosterone and Endothelin Hypertension, February 1, 2003; 41(2): 230 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M MacKenzie, R. Fraser, J. M. Connell, and E. Davies Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 214 - 221. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |